Can-Fite stock rises after discovering effect of Namodenoson in pancreatic cancer
Sean Anthony Eddy
- Can-Fite BioPharma (NYSE:CANF) stock rose ~6% on Tuesday after the company said it discovered the mechanism of action (MOA) involved with the anti-cancer effect of Namodenoson in pancreatic cancer.
- The company noted that Namodenoson de-regulates the Wnt signal transduction pathway, a key modulator of pancreatic cancer cell growth.
- The discovery was made when analyzing data from pre-clinical studies in which cells of a patient with advanced pancreatic cancer were exposed to Namodenoson, which had a significant anti-cancer effect, Can-Fite noted.
- This is the same MOA at work for Namodenoson in liver cancer, according to the company.
- Can-Fite said Namodenoson is currently under a phase 3 trial to treat advanced liver cancer and has completely cleared cancer in a patient with advanced liver cancer who remains cancer-free six years after starting therapy.
- "Knowing Namodenoson’s mechanism of action in pancreatic cancer is an important step in moving this indication toward potential partnerships. Our findings inform potential dosage and study design and increase the probability of success in human trials," said Can-Fite CEO Pnina Fishman.